- Home
- PRLD vs VATE Comparison
PRLD vs VATE Comparison
Compare PRLD & VATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRLD | VATE |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 74.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PRLD | VATE |
|---|---|---|
| Price | $2.11 | $5.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 286.6K | 16.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $4.05 |
| 52 Week High | $4.22 | $13.19 |
Technical Indicators
Market Signals| Indicator | PRLD | VATE |
|---|---|---|
| Relative Strength Index (RSI) | 50.15 | 43.26 |
| Support Level | $1.95 | $5.15 |
| Resistance Level | $2.37 | $5.54 |
| Average True Range (ATR) | 0.21 | 0.31 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 59.65 | 11.24 |
Price Performance
Historical ComparisonAbout PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.